Published in Clin Auton Res on October 01, 2002
Glycemic control and hypoglycemia: is the loser the winner? Diabetes Care (2008) 1.81
Mini-review: impact of recurrent hypoglycemia on cognitive and brain function. Physiol Behav (2010) 1.00
Gastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion. Obesity (Silver Spring) (2015) 0.85
Reversible Adrenal Insufficiency in Three Patients With Post-Roux-en-Y Gastric Bypass Noninsulinoma Pancreatogenous Hypoglycemia Syndrome. J Investig Med High Impact Case Rep (2014) 0.79
Recurrent Hypoglycemia Increases Anxiety and Amygdala Norepinephrine Release During Subsequent Hypoglycemia. Front Endocrinol (Lausanne) (2015) 0.75
Baroreflex Sensitivity Impairment During Hypoglycemia: Implications for Cardiovascular Control. Diabetes (2015) 0.75
Challenges in Modelling Hypoglycaemia-Associated Autonomic Failure: A Review of Human and Animal Studies. Int J Endocrinol (2016) 0.75
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Hypoglycemia in diabetes. Diabetes Care (2003) 6.19
Autonomic contribution to blood pressure and metabolism in obesity. Hypertension (2006) 2.25
Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care (2010) 1.71
Impaired glucose tolerance in rats fed low-carbohydrate, high-fat diets. Am J Physiol Endocrinol Metab (2013) 1.54
The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications (2011) 1.29
The role of GM-CSF in adipose tissue inflammation. Am J Physiol Endocrinol Metab (2008) 1.26
Effects of low and moderate antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes. Diabetes (2004) 1.20
A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf (2012) 1.17
Exercise-related hypoglycemia in diabetes mellitus. Expert Rev Endocrinol Metab (2011) 1.11
Acute, same-day effects of antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes mellitus. Am J Physiol Endocrinol Metab (2006) 1.05
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Leptin: metabolic control and regulation. J Diabetes Complications (2003) 1.03
Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes (2008) 1.03
Effect of antecedent hypoglycemia on counterregulatory responses to subsequent euglycemic exercise in type 1 diabetes. Diabetes (2003) 1.01
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs (2014) 1.00
Estrogen blunts neuroendocrine and metabolic responses to hypoglycemia. Diabetes (2003) 0.98
Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes (2008) 0.98
Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone (2006) 0.93
Hypothalamic control of energy and glucose metabolism. Rev Endocr Metab Disord (2011) 0.91
The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes (2008) 0.90
Glucoregulation during and after exercise in health and insulin-dependent diabetes. Exerc Sport Sci Rev (2005) 0.89
Cortisol acts through central mechanisms to blunt counterregulatory responses to hypoglycemia in conscious rats. Diabetes (2003) 0.89
Brain region-dependent effects of dexamethasone on counterregulatory responses to hypoglycemia in conscious rats. Am J Physiol Regul Integr Comp Physiol (2004) 0.87
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications? Curr Diabetes Rev (2013) 0.87
Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium. Diabetes (2012) 0.87
Effects of antecedent GABAA activation with alprazolam on counterregulatory responses to hypoglycemia in healthy humans. Diabetes (2010) 0.86
Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother (2011) 0.86
Effect of differing antecedent hypoglycemia on counterregulatory responses to exercise in type 1 diabetes. Am J Physiol Endocrinol Metab (2006) 0.85
Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care (2010) 0.85
Effects of differing antecedent increases of plasma cortisol on counterregulatory responses during subsequent exercise in type 1 diabetes. Diabetes (2009) 0.85
Effect of gender on counterregulatory responses to euglycemic exercise in type 1 diabetes. J Clin Endocrinol Metab (2002) 0.84
Effects of oral carbohydrate on autonomic nervous system counterregulatory responses during hyperinsulinemic hypoglycemia and euglycemia. Am J Physiol Endocrinol Metab (2008) 0.84
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2015) 0.84
Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complications (2007) 0.84
Effect of sex on counterregulatory responses to exercise after antecedent hypoglycemia in type 1 diabetes. Am J Physiol Endocrinol Metab (2004) 0.84
Antecedent short-term central nervous system administration of estrogen and progesterone alters counterregulatory responses to hypoglycemia in conscious male rats. Am J Physiol Endocrinol Metab (2007) 0.83
Differing physiological effects of epinephrine in type 1 diabetes and nondiabetic humans. Am J Physiol Endocrinol Metab (2005) 0.83
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol (2011) 0.82
Basal insulin treatment in type 2 diabetes. Diabetes Technol Ther (2011) 0.82
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol (2013) 0.82
NO synthase inhibition increases aldosterone in humans. Hypertension (2004) 0.82
The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol (2010) 0.82
Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther (2012) 0.81
The effects of dehydroepiandrosterone sulfate on counterregulatory responses during repeated hypoglycemia in conscious normal rats. Diabetes (2004) 0.80
Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother (2012) 0.79
Effects of glycemic control on target organ responses to epinephrine in type 1 diabetes. Am J Physiol Endocrinol Metab (2005) 0.79
Caffeine: a cause of insulin resistance? Diabetes Care (2002) 0.78
Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Curr Diab Rep (2008) 0.78
Physical activity in adolescents with type 1 diabetes: is more better for glycemic control? Pediatr Diabetes (2009) 0.78
Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am J Physiol Endocrinol Metab (2008) 0.77
Optimizing combination therapy for type 2 diabetes in adolescents and adults: a case-based approach. J Fam Pract (2004) 0.76
Hypoglycemia and vascular disease. Clin Chem (2010) 0.76
Metabolic consequences of exercise-associated autonomic failure. Exerc Sport Sci Rev (2006) 0.76
Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2012) 0.76
New concepts in diabetes: how multihormonal regulation can improve glycemic control. J Manag Care Pharm (2004) 0.76
Diabetes: Hypoglycemia-a new approach to an old problem. Nat Rev Endocrinol (2009) 0.76
The cardiovascular effects of insulin. Expert Opin Drug Saf (2014) 0.75
Discontinued in 2013: diabetic drugs. Expert Opin Investig Drugs (2014) 0.75
Prior exercise and the response to insulin-induced hypoglycemia in the dog. Am J Physiol Endocrinol Metab (2002) 0.75
Forebrain and hindbrain effects of ethanol on counterregulatory responses to hypoglycemia in conscious rats. Metabolism (2007) 0.75
Early intervention to achieve optimal outcomes in type 2 diabetes: a case presentation. Clin Cornerstone (2006) 0.75
The endocannabinoid system as a target for obesity treatment. Clin Cornerstone (2008) 0.75
Leptin responses to antecedent exercise and hypoglycemia in healthy and type 1 diabetes mellitus men and women. J Diabetes Complications (2003) 0.75
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2014) 0.75